Forty years experience of treating cancer of unknown primary (Q36846898)

16 August 2017

1 reference

title

Forty years experience of treating cancer of unknown primary (English)

1 reference

16 August 2017

Nicholas Pavlidis

1

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

46

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

592-601

1 reference

Diagnostic and therapeutic management of cancer of an unknown primary

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Cancer of unknown primary (CUP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Metastases of undetermined source

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Microvessel density in unknown primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Specific chromosome change, i(12p), in testicular tumours?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Mitomycin C, Epirubicin and Cisplatin versus Mitomycin C Alone as Therapy for Carcinoma of Unknown Primary Origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

A randomized Phase II trial in patients with carcinoma of an unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Response of carcinoma of unknown primary site affecting bone to thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Hepatic metastases from carcinomas of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02841860701243095

10.1080/02841860701243095

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference